ClinicalTrials.gg
Drug

trenibotulinumtoxinE clinical trials

Also written AGN-151586.

studies test it
10
open now
0
in phase 3
4
first study started
2019

How each study uses trenibotulinumtoxinE is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
15 Jul 2026 · Boey · EMEA/H/C/006420 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

AGN-151586
10

Studies by the year they started

10 studies that test it; most in 2022 (4)

Studies that test trenibotulinumtoxinE, by start year
YearStudies
20191
20224
20242
20251
20262

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
2
Phase 3
4

Who runs them

Industry 10 · Other 0

AbbVie (9) · Allergan (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test trenibotulinumtoxinE.

Studies

Open first, then newest update. How each study uses trenibotulinumtoxinE is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 10